Chester County News and Community Website
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced a key milestone in its ACESOT-1051 clinical trial, as the first patient with HPV-positive (HPV+) head and neck squamous cell carcinoma (HNSCC) …
Aprea Therapeutics Advances ACESOT-1051 Clinical Trial with Key Patient Dosing Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE), a clinical-stage biopharmaceutical company, shared its financial results for 2024 and provided a progress update on its lead programs aimed at advancing cancer …
Aprea Therapeutics Reports 2024 Financial Results and Updates on Clinical Innovations Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has entered into a Material Transfer Agreement (MTA) with MD Anderson Cancer Center to advance preclinical studies of its WEE1 kinase inhibitor, APR-1051. …
Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has announced significant advancements in its intellectual property portfolio, reinforcing the company’s leadership in the development of DNA Damage Response (DDR) therapeutics for …
Aprea Therapeutics Strengthens Patent Portfolio to Advance Oncology Innovation Read More DOYLESTOWN, PA — Aprea Therapeutics (Nasdaq: APRE) has announced a key update in its ongoing Phase 1/2a ABOYA-119 clinical trial for ATRN-119, aimed at treating advanced solid tumors with DNA damage …
Aprea Therapeutics Updates ABOYA-119 Trial with Twice Daily Dosing Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) released its third-quarter financial results for 2024, reporting key advancements in its clinical-stage therapeutic candidates. The company is making significant strides in …
Aprea Therapeutics Reports Q3 Financials and Advances in Clinical Trials Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) recently showcased preliminary safety results for its WEE1 inhibitor, APR-1051, at the EORTC-NCI-AACR Symposium in Barcelona. This data comes from ACESOT-1051, a Phase …
Aprea Therapeutics Presents Promising Safety Data for WEE1 Inhibitor at International Symposium Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has announced the appointment of Dr. Philippe Pultar as its senior medical advisor to bolster the development of APR-1051, a promising WEE1 inhibitor. …
Aprea Therapeutics Welcomes Dr. Philippe Pultar as Senior Medical Advisor Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has released its financial results for the second quarter ending June 30, 2024, alongside significant business updates that highlight the company’s strategic …
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Progress in Clinical Trials Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced that the first patient has been dosed in its Phase 1 ACESOT-1051 study. The trial is evaluating APR-1051, a daily oral …
Aprea Therapeutics Begins Phase 1 Trial for New Cancer Drug Read More